Zervimesine

Zervimesine
Clinical data
Other namesCT-1812; CT1812; Elayta
Drug classSigma σ2 receptor antagonist
Identifiers
  • 4-[3-methyl-3-(5-methylsulfonyl-1,3-dihydroisoindol-2-yl)butyl]-2-[(2-methylpropan-2-yl)oxy]phenol
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC24H33NO4S
Molar mass431.59 g·mol−1
3D model (JSmol)
  • CC(C)(C)OC1=C(C=CC(=C1)CCC(C)(C)N2CC3=C(C2)C=C(C=C3)S(=O)(=O)C)O
  • InChI=1S/C24H33NO4S/c1-23(2,3)29-22-13-17(7-10-21(22)26)11-12-24(4,5)25-15-18-8-9-20(30(6,27)28)14-19(18)16-25/h7-10,13-14,26H,11-12,15-16H2,1-6H3
  • Key:ISQAPFMBJFZOLG-UHFFFAOYSA-N

Zervimesine (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name;[1] developmental code name CT-1812 OR CT1812; tentative brand name Elayta) is a sigma σ2 receptor antagonist which is under development for the treatment of Alzheimer's disease, dementia, dry age-related macular degeneration, and other indications.[2][3][4]

The sigma σ2 receptor is a binding site for β-amyloid oligomers.[4] Zervimesine has been found to diplace β-amyloid oligomers from the sigma σ2 receptor in both preclinical and clinical studies.[4] As of 2024, effectiveness data on zerimesine for treatment of Alzheimer's disease are still lacking.[4]

Zervimesine is under development by Cognition Therapeutics.[2] As of July 2025, it is in phase 2 clinical trials for Alzheimer's disease, dementia, and dry age-related macular degeneration and is in preclinical research for Parkinson's disease.[2] The drug was also being developed for treatment of other cognition disorders, but development for this indication was discontinued.[2]

See also

References

  1. ^ "Proposed INN: List 133 International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. 39 (2). 2025.
  2. ^ a b c d "Cognition Therapeutics". AdisInsight. 14 July 2025. Retrieved 27 July 2025.
  3. ^ Kaur G, Dar ZA, Bajpai A, Singh R, Bansal R (2024). "Clinical Update on an Anti-Alzheimer Drug Candidate CT1812: A Sigma-2 Receptor Antagonist". Clinical Therapeutics. 46 (11): e21 – e28. doi:10.1016/j.clinthera.2024.08.013. PMID 39289058. Retrieved 27 July 2025.
  4. ^ a b c d Thitilertdecha P, Brimson JM (18 October 2024). "CT1812, a Small Molecule Sigma-2 Receptor Antagonist for Alzheimer's Disease Treatment: A Systematic Review of Available Clinical Data". Journal of Alzheimer's Disease. 101 (s1): S115 – S128. doi:10.3233/JAD-230994. PMID 39422939. Retrieved 27 July 2025.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.